Triasima Portfolio Management inc. Sells 7,138 Shares of Amgen Inc. (NASDAQ:AMGN)

Triasima Portfolio Management inc. cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 62.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,244 shares of the medical research company’s stock after selling 7,138 shares during the period. Triasima Portfolio Management inc.’s holdings in Amgen were worth $1,106,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new stake in Amgen in the third quarter worth $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the third quarter worth $29,000. Matrix Trust Co bought a new stake in Amgen in the third quarter worth $36,000. Heck Capital Advisors LLC bought a new stake in Amgen in the fourth quarter worth $36,000. Finally, Livelsberger Financial Advisory bought a new stake in Amgen in the third quarter worth $56,000. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.69% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on AMGN. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Royal Bank of Canada restated an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Jefferies Financial Group restated a “buy” rating and issued a $380.00 price objective on shares of Amgen in a research report on Tuesday, November 12th. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Finally, UBS Group decreased their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus target price of $314.83.

Amgen Stock Down 3.3 %

Shares of Amgen stock opened at $297.78 on Friday. The company has a market cap of $160.07 billion, a price-to-earnings ratio of 38.13, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56. The company’s 50 day moving average is $272.04 and its 200 day moving average is $303.51. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Research analysts anticipate that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.